Amedisys Partners With NVoq To Improve Clinician Experience
Zacks Investment Research | Nov 17, 2019 10:02PM ET
Amedisys, Inc. (NASDAQ:AMED) , in its effort to upgrade its offerings for non-acute-care services, has collaborated with nVoq, a provider of HIPAA compliant speech recognition solutions for the healthcare industry. The partnership will leverage nVoq's technology platform within Amedisys' home health and hospice business. Further, nVoq's platform supports mobile and care center-based medical professionals in 38 states in the United States and more than 300 locations.
Per the terms of the agreement, Amedisys’ clinicians will be able to accurately capture patient narratives at a much faster rate at the point of care, with nVoq.Mobile Voice. This will help to streamline and simplify the caregiver’s workflow. Apart from this, value-added automation can be harnessed by desktop users through the nVoq platform.
The partnership will thereby strengthen Amedisys’ position in the global home health and hospice market.
Rationale Behind the Partnership
Per Amedisys’ management, the collaboration will equip its home health and hospice segments with the medically relevant speech-to-text capability of nVoq. Amedisys believes that this will improve patient experience, clinician satisfaction and business efficiencies.
Recent Developments
Amedisys signed a deal in July to acquire regulatory assets that will allow it to conduct home health care operations at more counties in New York. The company also signed an agreement with ClearCare in July to establish a partnership between Amedisys’ home-health centers and personal care agencies, helping caregivers of patients to coordinate using ClearCare.
Amedisys finalized an acquisition deal with RoseRock Healthcare (a hospice care provider in Tulsa, OK) in April. Per the terms of the agreement, Amedisys acquired almost all assets of RoseRock, thus expanding Amedisys’ operational capabilities.
Further, Amedisys completed the acquisition of Compassionate Care Hospice (a hospice provider headquartered in Parsippany, NJ). The deal enabled Amedisys to acquire 100% ownership interest in Compassionate Care Hospice for a fixed price of $340 million, thus expanding Amedisys’ hospice footprint.
Industry Prospects
Per a report by Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.